AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8506890
Drug: Standardized garlic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized garlic powder tablets (300 mg three times a day)
Trial: 24286115
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart administered by InsuJet
Trial: 24286115
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart administered by FlexPen
Trial: 18695272
Drug: Oral salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral salbutamol (0.1 mg/kg/dose) three times a day for 7 days
Trial: 18695272
Drug: Oral salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral salbutamol (0.1 mg/kg/dose)
Trial: 12127929
Drug: Ala‐Gln group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ala‐Gln group received 0.972 g amino acids/kg/day and 0.417 g of L‐alanyl‐L‐glutamine (Ala‐Gln)/kg/day.
Trial: 12127929
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Conv) received 1.5 g amino acids/kg/day.
Trial: 1697824
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin administration
Trial: 668268
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml of aqueous ethanol diluted to 25% administered orally
Trial: 30590412
Drug: Dolutegravir (DTG)-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir (DTG)-based therapy
Trial: 30590412
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor (PI/r)-based therapy
Trial: 16709215
Drug: Toremifene 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene 20 mg daily
Trial: 11706099
Drug: 9 mg
RxNorm normalized name: fiber 469 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg IA r‐proUK over 120 minutes plus IV fixed‐dose heparin
Trial: 11706099
Drug: IV fixed‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV fixed‐dose heparin alone
Trial: 11706099
Drug: r‐proUK treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐proUK treatment
Trial: 9681371
Drug: Pemoline 10
RxNorm normalized name: pemoline 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemoline 10 mg
Trial: 9681371
Drug: Pemoline 20
RxNorm normalized name: pemoline 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemoline 20 mg
Trial: 9681371
Drug: Pemoline 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemoline 30 mg
Trial: 9681371
Drug: Pemoline 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemoline 40 mg
Trial: 2371369
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day haloperidol
Trial: 2371369
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day haloperidol
Trial: 2371369
Drug: 80 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/day haloperidol
Trial: 2553993
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with IFN-beta and IFN-gamma
Trial: 1106935
Drug: Digoxin solution
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin solution in capsule form
Trial: 1106935
Drug: Digoxin tablets
RxNorm normalized name: Digoxin Tablets
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin tablets with 97% dissolution rate
Trial: 1106935
Drug: Digoxin formulations
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin formulations
Trial: 12194393
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml 2% lidocaine
Trial: 27595956
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml 1% lidocaine
Trial: 24355668
Drug: Daily self-weighing
RxNorm normalized name: DAILY SELF DISCOVERY SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily self-weighing intervention
Trial: 22173280
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg alone
Trial: 22173280
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg co-administered with gemfibrozil 600 mg
Trial: 20848164
Drug: midazolam (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: midazolam (0.04 mg/kg)
Trial: 20848164
Drug: droperidol (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: droperidol (0.1 mg/kg)
Trial: 17851194
Drug: NICE appraisal
RxNorm normalized name: nicergoline
DrugBank: Nicergoline (DB00699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NICE appraisal of cholinesterase inhibitors
Trial: 12456899
Drug: EMLA on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA on the skin and orally administered placebo (sterile water)
Trial: 10525592
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg cisatracurium (3x ED(95))
Trial: 10525592
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg cisatracurium (2x ED(95))
Trial: 10525592
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg atracurium (2x ED(95))
Trial: 10525592
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three groups (0.1 mg/kg cisatracurium, 0.15 mg/kg cisatracurium, 0.5 mg/kg atracurium)
Trial: 7018179
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 5 mg orally
Trial: 7018179
Drug: Pindolol 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol 1.0 mg i.v.
Trial: 7018179
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ISDN and pindolol
Trial: 6656169
Drug: 3100 NOON-Units
RxNorm normalized name: NOON Cartessa Accelerate Program KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3100 NOON-Units (NU) with 3 injections in group A
Trial: 6656169
Drug: 9100 NOON-Units
RxNorm normalized name: NOON Cartessa Accelerate Program KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9100 NOON-Units (NU) with 6 injections in group B
Trial: 24474647
Drug: 9-beam lasercomb
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-beam lasercomb treatment in female subjects
Trial: 24474647
Drug: 12-beam lasercomb
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-beam lasercomb treatment in female subjects
Trial: 24474647
Drug: 7-beam lasercomb
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-beam lasercomb treatment in male subjects
Trial: 24474647
Drug: 9-beam lasercomb
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-beam lasercomb treatment in male subjects
Trial: 24474647
Drug: 12-beam lasercomb
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-beam lasercomb treatment in male subjects
Trial: 17484373
Drug: Lactulose 0
RxNorm normalized name: lactulose 0.4 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose 0 g (placebo)
Trial: 17484373
Drug: Lactulose 2
RxNorm normalized name: lactulose 2500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose 2 g (low-dose)
Trial: 17484373
Drug: Lactulose 4
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lactulose 4 g (high-dose)
Trial: 16286541
Drug: 1 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/kg of IVIG on day 1 and placebo on day 2 (group 1)
Trial: 16286541
Drug: 1 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/kg of IVIG on 2 consecutive days (group 2)
Trial: 10588559
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL 1% lidocaine with epinephrine 1:200,000
Trial: 10588559
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL 1% lidocaine without epinephrine
Trial: 8961492
Drug: Morphine via
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine via patient-controlled analgesia system
Trial: 1762067
Drug: R-ibuprofen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-ibuprofen (600 mg) plus S-[aromatic-2H4]ibuprofen (10 mg)
Trial: 1762067
Drug: S-ibuprofen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ibuprofen (600 mg)
Trial: 1762067
Drug: Racemic ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Racemic ibuprofen (800 mg) plus S-[aromatic-2H4]ibuprofen (10 mg)
Trial: 1762067
Drug: Racemic ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Racemic ibuprofen
Trial: 1762067
Drug: S-ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ibuprofen
Trial: 7044098
Drug: Cisplatin 120
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 120 mg/m2
Trial: 7044098
Drug: Cisplatin 60
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 60 mg/m2
Trial: 7044098
Drug: Cisplatin 60
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 60 mg/m2 to 120 mg/m2 crossover
Trial: 7044098
Drug: Cisplatin 60
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 60 mg/m2 and 120 mg/m2
Trial: 29017158
Drug: n-3 polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 polyunsaturated fatty acids (PUFAs) 2,700 mg/day
Trial: 22072466
Drug: Conventional injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional injection technique (CI)
Trial: 22072466
Drug: Proximal phalanx
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proximal phalanx injection technique (P1I)
Trial: 19336509
Drug: Cholecalciferol (D3)
RxNorm normalized name: CHOLECALCIFEROL (D3) 50MCG/DROP
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (D3) - 50,000 IU weekly
Trial: 19336509
Drug: Ergocalciferol (D2)
RxNorm normalized name: ERGOCALCIFEROL (D2) 200MCG/ML ORAL DROPS
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ergocalciferol (D2) - 50,000 IU weekly
Trial: 19336509
Drug: UV light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UV light therapy - exposed skin to UV light five times a week
Trial: 17719312
Drug: Perindopril (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (2 to 4 mg)
Trial: 10361264
Drug: Griseofulvin plus
RxNorm normalized name: Griseofulvin
DrugBank: Griseofulvin (DB00400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Griseofulvin plus oral prednisolone
Trial: 1773708
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin alone
Trial: 1773708
Drug: Syringe mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syringe mixed regular and NPH insulin
Trial: 7333003
Drug: Inhaled metaproterenol
RxNorm normalized name: metaproterenol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled metaproterenol given 10 min before exercise
Trial: 7333003
Drug: Inhaled metaproterenol
RxNorm normalized name: metaproterenol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled metaproterenol given 1 hr before exercise
Trial: 7333003
Drug: Metaproterenol tablets
RxNorm normalized name: metaproterenol Oral Tablet
DrugBank: Orciprenaline (DB00816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metaproterenol tablets given 1 hr before exercise
Trial: 7333003
Drug: Metaproterenol tablets
RxNorm normalized name: metaproterenol Oral Tablet
DrugBank: Orciprenaline (DB00816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metaproterenol tablets given 2 hr before exercise
Trial: 31413896
Drug: Botulinum neurotoxin
RxNorm normalized name: Botulinum neurotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum neurotoxin type A treatment
Trial: 30006297
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D deficiency ([25(OH)D] < 20 ng/ml)
Trial: 27858079
Drug: bFGF 35000IU
RxNorm normalized name: bFGF
DrugBank: Basic Fibroblast Growth Factor (DB14131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bFGF 35000IU + normal saline 20 mL, compression inhalation, day 1, every 20min, continued for 3 d
Trial: 27858079
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline 5 mL + dexamethasone 5 mg + gentamicin 80000 U + chymotrypsin 4000 U, compression inhalation, twice a day, every 20 min, continued for 3 d
Trial: 25070547
Drug: Continuous cycling
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous cycling (CC) using 20 mcg ethinyl estradiol/100 mcg levonorgestrel with no hormone-free interval
Trial: 25070547
Drug: Increased dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dose (ID) using 30 mcg ethinyl estradiol/150 mcg levonorgestrel cyclically
Trial: 18490196
Drug: CSE 900
RxNorm normalized name: PHOSPHORIC ACID 1500 mg in 10 L / BENZALKONIUM CHLORIDE 400 mg in 10 L / N-ALKYL ETHYLBENZYL DIMETHYL AMMONIUM CHLORIDE (C12-C14) 400 mg in 10 L TOPICAL LIQUID [StepSept CSE-200]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSE 900 mg
Trial: 15666173
Drug: Milk thistle
RxNorm normalized name: MILK THISTLE
DrugBank: Milk thistle (DB14375)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk thistle (450 mg extract capsules t.i.d. from day 2 to day 30)
Trial: 1625204
Drug: Bromocriptine (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (0, 1.2 and 2.5 mg given orally 2 hr before the cocaine injection)
Trial: 26940371
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three test solutions
Trial: 20620265
Drug: Monotherapy or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy or combination therapy for manic/mixed episodes
Trial: 20620265
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics (monotherapy or in combination)
Trial: 17936411
Drug: Adalimumab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (40 mg) every other week for the first 15 weeks
Trial: 17936411
Drug: Adalimumab (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (continuous treatment)
Trial: 9005787
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg intravenously twice a day for 3 days, then orally at the same dosage)
Trial: 3087678
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (22.5 cm2 mean dose)
Trial: 30953306
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of opt-out testing and financial incentives
Trial: 22127938
Drug: Reinforced feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinforced feedback in virtual environment (RFVE) therapy
Trial: 22127938
Drug: RFVE therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RFVE therapy in haemorrhagic group
Trial: 22127938
Drug: TNR therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNR therapy in haemorrhagic group
Trial: 22127938
Drug: RFVE therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RFVE therapy in ischaemic group
Trial: 22127938
Drug: TNR therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNR therapy in ischaemic group
Trial: 19359142
Drug: Combination message
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination message (high fiber/low saturated fat)
Trial: 16903985
Drug: r-hGH 4
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-hGH 4 mg daily (group A)
Trial: 16903985
Drug: Drug-related side
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-related side effects in group A
Trial: 16903985
Drug: Drug-related side
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-related side effects in group B
Trial: 11743379
Drug: Amrinone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amrinone (5 mg/ml)
Trial: 10975630
Drug: Alcohol (0.62
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.62 g/kg)
Trial: 2500472
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy without acute cardiac catheterization
Trial: 19260631
Drug: Postoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative treatment with hemisuccinate of hydrocortisone or dexamethasone
Trial: 19260631
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy without cortisone
Trial: 16444031
Drug: Prestarium (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prestarium (an angiotensin-converting enzyme inhibitor)
Trial: 10475140
Drug: Tilidine/Naloxone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilidine/Naloxone (50 mg/4 mg)
Trial: 10475140
Drug: Bromfenac (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromfenac (75 mg)
Trial: 10475140
Drug: Bromfenac (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromfenac (25 mg)
Trial: 10475140
Drug: Bromfenac (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromfenac (50 mg)
Trial: 2143687
Drug: MCV +
RxNorm normalized name: Methylcellulose
DrugBank: Methylcellulose (DB11228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCV + CYP 300 mg/m2
Trial: 2143687
Drug: MCV +
RxNorm normalized name: Methylcellulose
DrugBank: Methylcellulose (DB11228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCV + CYP 150 mg/m2
Trial: 2143687
Drug: MCV +
RxNorm normalized name: Methylcellulose
DrugBank: Methylcellulose (DB11228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCV + CYP 75 mg/m2
Trial: 322242
Drug: Floctafenine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Floctafenine (200 mg)
Trial: 26400023
Drug: Decitabine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decitabine (15 mg/m² every 8 h for 3 days)
Trial: 21546216
Drug: Artemisinin 100mg
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin 100mg twice a day for 10 weeks
Trial: 18439596
Drug: recombinant follicle-stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant follicle-stimulating hormone (FSH)
Trial: 17481615
Drug: 750-mug tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750-mug tablets (2 tablets of 0.75 mg each)
Trial: 15621576
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) treatment
Trial: 11677390
Drug: All five
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All five techniques administered to another 19 participants
Trial: 9840526
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (cisplatin 60 mg/m2 and epirubicin 110 mg/m2 on Day 1 for 2-3 cycles) followed by radiotherapy (66-74 Gy to primary tumor, median 71 Gy; 60-76 Gy to neck, median 66 Gy)
Trial: 9840526
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (cisplatin and epirubicin) followed by radiotherapy
Trial: 3186777
Drug: Sunflower seed
RxNorm normalized name: SUNFLOWER SEED
DrugBank: Sunflower seed (DB10907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunflower seed and linseed oil capsules
Trial: 86666
Drug: Oral antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antimicrobial prophylaxis (metronidazole and kanamycin)
Trial: 28435054
Drug: Palucorcel (human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palucorcel (human umbilical tissue-derived cells) administered in 33 eyes